Kite to Acquire Interius BioTherapeutics: A Leap Forward in In Vivo Cell Therapy
Kite Pharma, a Gilead company, has announced a definitive agreement to acquire Interius BioTherapeutics for $350 million, marking a pivotal step in the future of cell therapy.
Unlike traditional CAR T-cell therapies—which require harvesting, engineering, and reinfusing a patient’s cells—Interius’s novel in vivo platform creates therapeutic CAR T-cells directly inside the patient’s body through a single intravenous infusion. This next-generation approach has the potential to make treatment faster, more scalable, and more accessible—especially for patients with aggressive or advanced disease.
“With Interius’s innovative platform and Kite’s deep expertise, we aim to advance best-in-class in vivo therapies to bring them to patients more efficiently,” said Cindy Perettie, EVP of Kite. The acquisition not only reduces the complexity of current CAR T treatments but could also eliminate the need for preconditioning chemotherapy and specialized manufacturing, broadening access to cell therapy worldwide.
Following the acquisition, Interius’s operations will integrate into Kite’s research team, establishing a new center of excellence in Philadelphia to accelerate the development of in vivo therapies across oncology and beyond.
This bold move positions Kite and Gilead at the forefront of next-generation cell therapy, underscoring the industry’s shift toward simpler, scalable, and more durable treatments for life-threatening diseases.
🔗 Read the full announcement here
Explore more
🎤 Career – Real career stories and job profiles of life science professionals. Discover current opportunities for students and researchers.
💼 Jobs – The latest job openings and internship alerts across academia and industry.
📢 Advertise with BioPatrika – Reach the Right Audience, Fast!
🛠️ Services – Regulatory support, patent filing assistance, and career consulting services.
